ArticleDermatology and therapy2026
Real-World Effectiveness and Safety of Tildrakizumab in Moderate-to-Severe Psoriasis: A Multicenter Experience in the Basque Country.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Real-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS).Pharmacy (Basel, Switzerland) · 2026Article
- Immunosenescence in Older Patients with Psoriasis: Mechanistic Insights and Opportunities for Biologic Therapy.Psoriasis (Auckland, N.Z.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTildrakizumab, an anti-interleukin (IL)-23p19 monoclonal antibody, is approved for the treatment of moderate-to-severe plaque psoriasis. Although pivotal clinical trials have shown its sustained efficacy and safety, real-world evidence (RWE) is crucial to assess its performance in routine clinical practice. The aim of this study is to evaluate the real-world effectiveness and safety of tildrakizumab in adult patients with moderate-to-severe plaque psoriasis in the Basque Country, northern Spain.
methodsWe conducted a multicenter, retrospective observational study, including 212 adult patients treated with tildrakizumab across five tertiary hospitals between November 2020 and April 2024. Clinical outcomes, including Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), and Physician Global Assessment (PGA) scores were collected at baseline and weeks 28, 52, 76, and 100-112. Safety data and reasons for treatment discontinuation were also recorded.
resultsAmong the 212 patients (median age 52.7 years, 56.56% male), most had long-standing psoriasis (median duration: 20.9 years) and multiple comorbidities. Over 80% had previously received biologic therapy. At week 52, 68.8% of patients with follow-up achieved PASI ≤ 3, and 72.7% reached a PGA of 0/1. Median PASI decreased from 11.21 at baseline to 2.51 at week 52. No serious treatment-related adverse events were reported. Discontinuation occurred in 41 patients (19.3%), mainly owing to primary or secondary failure and patient decision.
conclusionsTildrakizumab demonstrated high effectiveness and a favorable safety profile in this large, real-world multicenter cohort. These findings support its role as a reliable therapeutic option for patients with moderate-to-severe plaque psoriasis in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.